Loading...
•
Mar 31, 2025
Absci Q1 2025 Earnings Report
Absci reported a wider net loss and higher R&D expenses while launching its first clinical trial.
Key Takeaways
Absci reported Q1 2025 revenue of $1.2M with a net loss of $26.3M, driven by increased R&D investments. The company began dosing in its ABS-101 clinical trial and strengthened its pipeline momentum.
Revenue rose to $1.2M, up from $0.9M in Q1 2024
Net loss widened to $26.3M driven by increased R&D expenses
Cash and short-term investments reached $134M, supporting runway into 2027
Initiated first-in-human study for lead antibody program ABS-101
Forward Guidance
Absci plans to advance multiple programs through preclinical and clinical development while maintaining financial flexibility with its current cash runway into 2027.
Positive Outlook
- Cash position supports operations into H1 2027
- Interim data readout for ABS-101 expected in H2 2025
- ABS-201 Phase 1 initiation targeted for early 2026
- NHP data supports clinical development of ABS-201
- Strong pipeline including internal and partnered programs
Challenges Ahead
- Continued net losses expected due to R&D investments
- No commercial products yet generating recurring revenue
- High reliance on future partnerships to sustain growth
- Limited revenue diversification at this stage
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...